Usman Ajaz, MD
Rheumatology · Spokane, WANPI 1912261025
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,114 of the $10,839 with a category attached, or 84.1%. 33 manufacturers reported payments, led by Johnson & Johnson at 25.8% of the total.
Across 343 payments — averaging $31.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Amgen$2K
- AbbVie$2K
- Lilly USA, LLC$595
- AstraZeneca$543
- Pfizer$503
- plus $3K from 27 others
What the payments were for
- Consulting fees$1,68015%
- Travel & lodging$450%
- Food & beverage$9,11484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 36 | $2,797 |
| Amgen(2 entities) | 118 | $1,946 |
| AbbVie | 36 | $1,625 |
| Lilly USA, LLC | 20 | $595 |
| AstraZeneca(2 entities) | 14 | $543 |
| Pfizer | 25 | $503 |
| Janssen Scientific Affairs, LLC | 4 | $429 |
| GSK | 13 | $387 |
| Novartis | 16 | $384 |
| UCB, Inc. | 10 | $321 |
| ANI Pharmaceuticals, Inc. | 2 | $169 |
| Aurinia Pharma U.S., Inc. | 6 | $153 |
| Boehringer Ingelheim | 2 | $145 |
| Genentech USA, Inc. | 8 | $140 |
| Pacira Therapeutics, Inc. | 1 | $124 |
| Novo Nordisk | 6 | $87 |
| Mallinckrodt Hospital Products Inc. | 3 | $71 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Bayer | 3 | $42 |
| Recordati_rare_diseases_inc. | 2 | $38 |
| Tandem Diabetes Care, Inc. | 2 | $33 |
| Chiesi USA, Inc. | 2 | $32 |
| Biomarin Pharmaceutical Inc. | 2 | $30 |
| Sobi, Inc | 1 | $26 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Urgo Medical North America, LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| Cequr Corporation | 1 | $17 |
| Convatec Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,839 in reported general payments places this provider in the 85th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $80,276 |
| Hydroxychloroquine Sulfate | 135 | $5,811 |
| MethotrexateMethotrexate Sodium | 170 | $5,096 |
| Mycophenolate Mofetil | 16 | $3,095 |
| Leflunomide | 45 | $2,742 |
| Colchicine | 17 | $1,208 |
| Prednisone | 117 | $898 |
| Sulfasalazine | 19 | $732 |
| Celecoxib | 12 | $639 |
| Methylprednisolone | 54 | $394 |
| Gabapentin | 17 | $354 |
| Allopurinol | 39 | $306 |
| Folic Acid | 22 | $184 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Spokane
- Howard KenneySpokane$132K
- Eric MuellerSpokane$14K
- Michael CoanSpokane$10K
- Rebecca MunteanSpokane$8K
- Barbara JacobsSpokane$5K
- Penny SatherSpokane$4K
- Jeffrey ButlerSpokane$3K
- Raksha PradhanSpokane$2K
- Sean LasalleSpokane$992
- Lauren JohnsonSpokane$887
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.